248 related articles for article (PubMed ID: 15839955)
1. Review of gemcitabine-based combinations for platinum-resistant ovarian cancer.
Sehouli J
Int J Gynecol Cancer; 2005; 15 Suppl 1():23-30. PubMed ID: 15839955
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine in ovarian cancer.
Orlando M; Mandachain M
Semin Oncol; 2001 Jun; 28(3 Suppl 10):62-9. PubMed ID: 11510036
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine in ovarian cancer: an overview of safety and efficacy.
Kaufmann M; von Minckwitz G
Eur J Cancer; 1997 Jan; 33 Suppl 1():S31-3. PubMed ID: 9166098
[TBL] [Abstract][Full Text] [Related]
4. The role of gemcitabine in the treatment of ovarian cancer.
Ozols RF
Semin Oncol; 2000 Feb; 27(1 Suppl 2):40-7. PubMed ID: 10697035
[TBL] [Abstract][Full Text] [Related]
5. Role of gemcitabine in ovarian cancer treatment.
Lorusso D; Di Stefano A; Fanfani F; Scambia G
Ann Oncol; 2006 May; 17 Suppl 5():v188-94. PubMed ID: 16807454
[TBL] [Abstract][Full Text] [Related]
6. Second-line treatment of ovarian cancer with single-agent gemcitabine.
Markman M
Semin Oncol; 2002 Feb; 29(1 Suppl 1):9-10. PubMed ID: 11840414
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine in the treatment of ovarian cancer.
Hansen SW
Int J Gynecol Cancer; 2001; 11 Suppl 1():39-41. PubMed ID: 11489002
[TBL] [Abstract][Full Text] [Related]
8. [Gemicitabine in the treatment of epithelial ovarian cancer].
Pautier P; Gutierrez M; Lhomme C
Bull Cancer; 2002 Aug; 89 Spec No():S115-9. PubMed ID: 12449041
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma.
Rose PG
Int J Gynecol Cancer; 2005; 15 Suppl 1():18-22. PubMed ID: 15839954
[TBL] [Abstract][Full Text] [Related]
10. Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.
Markman M; Webster K; Zanotti K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 2003 Sep; 90(3):593-6. PubMed ID: 13678730
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
Yoshino K; Kamiura S; Yokoi T; Nakae R; Fujita M; Takemura M; Adachi K; Wakimoto A; Nishizaki T; Shiki Y; Tsutsui T; Kanda Y; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Sawada K; Tomimatsu T; Kimura T
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1239-1247. PubMed ID: 29080971
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives.
Lorusso D; Ferrandina G; Fruscella E; Marini L; Adamo V; Scambia G
Int J Gynecol Cancer; 2005; 15(6):1002-13. PubMed ID: 16343176
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
Raspagliesi F; Zanaboni F; Vecchione F; Hanozet F; Scollo P; Ditto A; Grijuela B; Fontanelli R; Solima E; Spatti G; Scibilia G; Kusamura S
Oncology; 2004; 67(5-6):376-81. PubMed ID: 15713993
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
Lund B; Hansen OP; Theilade K; Hansen M; Neijt JP
J Natl Cancer Inst; 1994 Oct; 86(20):1530-3. PubMed ID: 7932808
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine in the treatment of ovarian cancer.
Hansen SW; Tuxen MK; Sessa C
Ann Oncol; 1999; 10 Suppl 1():51-3. PubMed ID: 10219453
[TBL] [Abstract][Full Text] [Related]
16. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer.
Kodaz H; Hacibekiroglu I; Turkmen E; Erdogan B; Elpen C; Uzunoglu S; Cicin I
Tumori; 2015; 101(1):36-40. PubMed ID: 25702671
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.
Friedlander M; Millward MJ; Bell D; Bugat R; Harnett P; Moreno JA; Campbell L; Varette C; Ripoche V; Kayitalire L
Ann Oncol; 1998 Dec; 9(12):1343-5. PubMed ID: 9932166
[TBL] [Abstract][Full Text] [Related]
18. Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W;
Onkologie; 2004 Feb; 27(1):58-64. PubMed ID: 15007250
[TBL] [Abstract][Full Text] [Related]
19. Activity of gemcitabine in platinum-resistant ovarian germ cell cancer.
Maas K; Daikeler T; Kanz L; Bokemeyer C
Eur J Cancer; 1996 Jul; 32A(8):1437-8. PubMed ID: 8869115
[No Abstract] [Full Text] [Related]
20. Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience.
Yoshino K; Hiramatsu K; Enomoto T; Fujita M; Ueda Y; Kimura T; Kobayashi E; Kiyohara Y; Tsutsui T; Kimura T
Anticancer Res; 2012 Sep; 32(9):4029-33. PubMed ID: 22993355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
